Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy.

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathies include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and paraprotein-associated demyelinating neuropathy. This review summarises the evidence from randomised controlled trials (RCTs) for the treatment of these conditions. It leads to the conclusions that: 1) steroids are beneficial in CIDP but not MMN and their efficacy in paraproteinaemic demyelinating neuropathy (PDN) is uncertain; 2) intravenous immunoglobulin (IVIg) produces short-term benefit in CIDP, MMN and IgM PDN. Its effect in IgG or IgA PDN has not been tested in RCTs; 3) plasma exchange (PE) also produces short-term benefit in CIDP and IgG or IgA PDN but probably not in MMN; 4) there is almost no information from RCTs concerning the possible benefits of immunosuppressive agents; and 5) volunteers are needed to write Cochrane systematic reviews of IVIg for MMN and of interventions for PDN associated with IgG and IgA.

• Authors: R A C Hughes
• Journal: Revue neurologique (Rev Neurol (Paris)) Vol. 158 Issue 12 Pt 2 Pg. S32-6 (Dec 2002) ISSN: 0035-3787 [Print] France
• PMID: 12690659 (Publication Type: Journal Article, Review)

Chemical References

• Immunoglobulins, Intravenous
• Immunosuppressive Agents

Topics

• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Immunosuppressive Agents (therapeutic use)
• Plasma Exchange (methods)
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (drug therapy, therapy)